viewCircassia Group PLC

Circassia Group Plc - Completion of Transaction

RNS Number : 1433O
Circassia Group Plc
28 May 2020

28 May 2020

Circassia Group plc

Completion of Transaction

Circassia Group plc ("Circassia" or "the Company") announces that the proposed transfer of the Tudorza and Duaklir assets to AstraZeneca first announced on 9 April 2020 has now completed.


Ian Johnson, Executive Chairman of Circassia, said:  "The completion of this transaction transforms Circassia into a debt-free business.  Niox® is a highly differentiated respiratory diagnostic platform that will be able to deliver long-term growth and enhanced shareholder returns."



For further information, please contact:

Circassia Group plc


Ian Johnson, Executive Chairman



c/o Peel Hunt

Michael Roller, CFO

Peel Hunt (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 7418 8900

James Steel / Oliver Jackson

finnCap (Joint Broker)

Tel: +44 (0) 20 7220 0500

Geoff Nash / Alice Lane

Numis Securities (Joint Broker)

Tel: +44 (0) 20 7260 1000

James Black / Duncan Monteith








This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Circassia Group PLC

Price: 31.6

Market: LSE
Market Cap: £119.13 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19